Bradley J . Monk, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Professor

Books

• Pediatric, Adolescent, & Young Adult Gynecology
  Mahdavi Ali, Cervix Cytology, Dysplasia, and Human Papillomavirus [Book Chapter] 2009
• Cancer Prevention
  Monk Bradley J., Human Papillomavirus Vaccine: A New Chance to Prevent Cervical Cancer [Book Chapter] 2007

Publications

• International journal of gynecological cancer
  Salani Ritu, A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04), p. ijgc-2024-005588 2024
• International journal of gynecological cancer
  Vergote I, P154 Tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase 3 INNOVATE/ENGOT-ov50 study
  29:Suppl 4, p. A152 - A153 2019
• International journal of gynecological cancer
  Oonk MHM, Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II
  29:Suppl 4, p. A14 - A14 2019
• International journal of gynecological cancer
  Tewari K, 393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
  29:Suppl 3, p. A162 - A162 2019
• Gynecologic oncology
  Shapira-Frommer R., Ofranergene obadenovec (VB-111) an anti-cancer gene therapy induces immunotherapeutic effect in platinum resistant ovarian cancer: Histopathology findings
  154, p. 231 - 232 2019
• Gynecologic oncology
  Pujade-Lauraine E., Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
  154, p. 21 - 22 2019
• Gynecologic oncology
  Longoria T.C., GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study
  149, p. 37 - 38 2018
• Journal of clinical oncology
  Madhavan Subha, A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers
  36:15_suppl, p. 6508 - 6508 2018
• Annals of oncology
  Monk B J, Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
  28 Suppl 8, p. viii40 2017
• Gynecologic oncology
  Monk B.J., A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study
  145, p. 220 - 221 2017
• Gynecologic oncology
  Dalton H.J., Current awareness and use of bevacizumab in advanced cervical cancer: A survey among US community oncologists
  145, p. 186 - 186 2017
• Gynecologic oncology
  Perkins Victoria, The Potential Role of Pelvic Radiation in Stage IVB Cervical Carcinoma
  143:1, p. 221 - 221 2016
• Annals of oncology
  Mirza M.R., gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)
  27, p. vi568 - vi568 2016
• Journal of the advanced practitioner in oncology
  Monk Bradley J., Ovarian Cancer: Current Treatment and Patient Management
  7:3, p. 271 - 273 2016
• Journal of clinical oncology
  Chan John K, Reply to F.M. Muggia
  34:8, p. 882 - 883 2016
• JAMA oncology
  Swisher Elizabeth M, Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma
  2:3, p. 370 - 372 2016
• Journal of gynecologic surgery
  Shields Kristin M., Ten-Year Food and Drug Administration Reporting on Robotic Complications in Gynecologic Surgery
  31:6, p. 331 - 335 2015
• Gynecologic oncology
  Shields K., Abstract 15: Cancer-related fatigue in gynecologic oncology patients undergoing chemotherapy
  137:3, p. 596 - 596 2015
• Gynecologic oncology
  Phippen N.T., Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: Results from a prospective multicenter phase III NRG Oncology/Gynecologic Oncolog
  138, p. 2 - 2 2015
• Journal of clinical oncology
  Herzog Thomas J, In assessing surrogate clinical trial end points: drug safety is a requisite
  33:13, p. 1511 - 1512 2015
• Gynecologic oncology
  Tewari K.S., Impact of treatment-induced neutropenia and thrombocytopenia on survival in patients with advanced ovarian cancer treated with chemotherapy plus bevacizumab: An NRG Oncology/Gynecologic Oncology Group ancillary data study
  137, p. 25 - 26 2015
• Gynecologic oncology
  Eskander R.N., Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study
  137, p. 28 - 28 2015
• Gynecologic oncology
  Waggoner S.E., Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): An NRG Oncology/Gynecologic Oncology Group study
  137, p. 143 - 144 2015
• Gynecologic oncology
  Ko E.M., Chemotherapy toxicity and quality of life in older women with advanced or recurrent endometrial cancer: An NRG Oncology — Gynecologic Oncology Group ancillary study
  137, p. 32 - 32 2015
• Gynecologic oncology
  Tewari K.S., Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study
  137, p. 12 - 12 2015
• Gynecologic oncology
  Fuh K.C., Differences in presentation and survival of Asians versus Caucasians with ovarian cancer: A Gynecologic Oncology Group ancillary study of 7914 patients
  137, p. 6 - 6 2015
• Clinical advances in hematology & oncology
  Tewari Krishnansu S, Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer
  12:11, p. 737 - 748 2014
• Journal of clinical oncology
  du Bois Andreas, Incorporation of pazopanib in maintenance therapy of ovarian cancer
  32:30, p. 3374 - 3381 2014
• Gynecologic oncology
  Herzog T.J., Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
  133, p. 41 - 42 2014
• Gynecologic oncology
  Monk B.J., Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: Exploratory analysis of phase III OVA-301 study
  133, p. 41 - 41 2014
• Gynecologic oncology
  Tewari K.S., High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: A Gynecologic Oncology Group (GOG) study
  133, p. 60 - 60 2014
• Gynecologic oncology
  Tewari K.S., Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: A Gynecologic Oncology Group (GOG) study
  133, p. 59 - 60 2014
• Gynecologic oncology
  Ferriss J.S., Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers
  133, p. 25 - 25 2014
• Gynecologic oncology
  Raspagliesi F., Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
  133, p. 57 - 57 2014
• Gynecologic oncology
  Craig C., The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
  131:1, p. 264 - 264 2013
• Journal of clinical oncology
  Benjamin I., Acquired drug resistance in gynecologic cancer detected by drug response marker testing
  29:15_suppl, p. 5068 - 5068 2011
• Journal of clinical oncology
  Poveda A., Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301
  29:15_suppl, p. 5067 - 5067 2011
• Journal of clinical oncology
  Monk B. J., Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
  29:15_suppl, p. 5046 - 5046 2011
• European journal of cancer (1990)
  Monk B.J., Quality of Life Outcomes of a Randomized, Placebo-Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian Cancer: a Gynecologic Oncology Group Study
  47, p. 12 - 12 2011
• Journal of clinical oncology
  Monk Bradley J., Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
  28:19, p. 3107 - 3114 2010
• Journal of clinical oncology
  Burger R. A., Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study
  28:18_suppl, p. LBA1 - LBA1 2010
• Journal of clinical oncology
  Monk B. J., Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG)
  28:15_suppl, p. 5046 - 5046 2010
• Journal of clinical oncology
  Fuh K., Characteristics and outcomes of pharmaceutical versus nonpharmaceutical affiliated phase III clinical trials on targeted agents for cancer therapy
  28:15_suppl, p. 5073 - 5073 2010
• Journal of clinical oncology
  Poveda A., Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a ph
  28:15_suppl, p. 5012 - 5012 2010
• Journal of clinical oncology
  Nguyen T., Trends and progress in phase III clinical trials on targeted agents in advanced cancers
  28:15_suppl, p. e15543 - e15543 2010
• International journal of gynecological cancer
  Monk Bradley J., Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds
  19:11 Suppl 2, p. S63 - S67 2009
• Cancer
  von Gruenigen Vivian E., Assessment of Factors That Contribute to Decreased Quality of Life in Gynecologic Oncology Group Ovarian Cancer Trials
  115:20, p. 4857 - 4864 2009
• Journal of clinical oncology
  Poveda A., Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD
  27:15_suppl, p. 5551 - 5551 2009
• Journal of clinical oncology
  Herzog T. J., Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone
  27:15_suppl, p. 5550 - 5550 2009
• Journal of clinical oncology
  Randall-Whitis L., Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial
  27:15_suppl, p. e16505 - e16505 2009
• American journal of obstetrics and gynecology
  Meltzer Sara M., Green tea catechins for treatment of external genital warts
  200:3, p. 233.e1 - 233.e7 2009
• International journal of gynecological cancer
  Gatcliffe T A, Wnt signaling in ovarian tumorigenesis
  18:5, p. 954 - 962 2008
• American journal of obstetrics and gynecology
  Monk Bradley J., Perspectives of cervical cytology in Russia - Reply
  199:2, p. E10 - E11 2008
• Journal of clinical oncology
  Schwartz P. E., An open-label, single arm, phase II study of IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21 days as second-line therapy in subjects with platinum-sensitive relapsed ovarian cancer: First stage results
  26:15_suppl, p. 16518 - 16518 2008
• Journal of clinical oncology
  Monk B. J., A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study
  26:15_suppl, p. LBA5504 - LBA5504 2008
• Journal of clinical oncology
  Tewari D., The clinical-pathologic factors relevant to intraperitoneal chemotherapy in ovarian cancer: An analysis of two Gynecologic Oncology Group trials
  26:15_suppl, p. 5549 - 5549 2008
• Journal of clinical oncology
  Wenzel L. B., Quality-of-life results of a randomized phase III trial of four cisplatin (Cis) containing doublet combinations in stage IVB cervical carcinoma: A gynecologic oncology group (GOG) study
  26:15_suppl, p. 5529 - 5529 2008
• Gynecologic oncology
  Wright Thomas C., Age considerations when vaccinating against HPV
  109:2, p. S40 - S47 2008
• Gynecologic oncology
  Herzog Thomas J., Initial lessons learned in HPV vaccination
  109:2, p. S4 - S11 2008
• Expert review of anticancer therapy
  Chase Dana M., Supportive care for women with gynecologic cancers
  8:2, p. 227 - 241 2008
• American journal of obstetrics and gynecology
  Herzog Thomas J., Reducing the burden of glandular carcinomas of the uterine cervix
  197:6, p. 566 - 571 2007
• Gynecologic oncology
  Monk Bradley J., The spectrum and clinical sequelae of human papillomavirus infection
  107:2, p. S6 - S13 2007
• American journal of obstetrics and gynecology
  Monk Bradley J., The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination
  197:4, p. 337 - 339 2007
• Expert review of anticancer therapy
  Han Ernest S, Bevacizumab in the treatment of ovarian cancer
  7:10, p. 1339 - 1345 2007
• Journal of clinical oncology
  Han E. S., Relationship of angiogenesis biomarkers and clinical response to bevacizumab (Bev) in persistent or recurrent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) patients treated in a Phase II Gynecologic Oncology Group study
  25:18_suppl, p. 21021 - 21021 2007
• Journal of clinical oncology
  Herzog T. J., Preliminary safety and efficacy results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
  25:18_suppl, p. 5518 - 5518 2007
• Journal of clinical oncology
  Moore D. H., Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: A multivariate analysis of three Gynecologic Oncology Group trials
  25:18_suppl, p. 5534 - 5534 2007
• Journal of clinical oncology
  Ueda S. M., Characteristics of a phase II study that predict for a positive phase III trial—A study of 383 clinical trials
  25:18_suppl, p. 6604 - 6604 2007
• Journal of clinical oncology
  Randall-Whitis L., Markers of angiogenesis in cervical cancer: A Gynecologic Oncology Group study
  25:18_suppl, p. 5536 - 5536 2007
• Journal of clinical oncology
  Liu P., A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy
  24:18_suppl, p. 5080 - 5080 2006
• International journal of gynecological cancer
  Calkins A., Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group
  16:2, p. 660 - 663 2006
• Current oncology reports
  Tewari Krishnansu S, Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer
  7:6, p. 419 - 434 2005
• Gynecologic oncology
  Tewari Devansu, Gene expression profiling of in vitro radiation resistance in cervical carcinoma: A feasibility study
  99:1, p. 84 - 91 2005
• The oncologist (Dayton, Ohio)
  Mahdavi Ali, Vaccines against human papillomavirus and cervical cancer: promises and challenges
  10:7, p. 528 - 538 2005
• Journal of clinical oncology
  Liu P.-Y., Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received “maintenance therapy”
  23:16_suppl, p. 5013 - 5013 2005
• Current oncology reports
  Wiley Dorothy J, Cervical cancer screening
  6:6, p. 497 - 506 2004
• Cancer
  Burger Robert A, Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: A Gynecologic Oncology Group Study
  101:1, p. 106 - 115 2004
• Cancer
  Monk Bradley, Human papillomavirus infection: Truth or consequences
  100:2, p. 225 2004
• American journal of obstetrics and gynecology
  Monk Bradley J, Does the ALTS trial apply to the community-based practitioner?
  188:6, p. 1381 - 1382 2003
• Obstetrics and gynecology clinics of North America
  Im Samuel S, New developments in the treatment of invasive cervical cancer
  29:4, p. 659 - 672 2002
• Gynecologic oncology
  Monk Bradley J., Development of an in Vitro Chemo-Radiation Response Assay for Cervical Carcinoma
  87:2, p. 193 - 199 2002
• Journal of lower genital tract disease
  McHale Michael T, Influence of serum and tissue micronutrient levels on the regression of untreated cervical intraepithelial neoplasia 2 and 3
  6:4, p. 220 - 224 2002
• Gynecologic oncology
  Chan John K., Laparoscopic Photodynamic Diagnosis of Ovarian Cancer Using 5-Aminolevulinic Acid in a Rat Model
  87:1, p. 64 - 70 2002
• Tewai Krishnansu S, Primary invasive carcinoma of the vagina : Treatment with interstitial brachytherapy 2001
• Proceedings of the National Academy of Sciences - PNAS
  Welsh John B., Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
  98:3, p. 1176 - 1181 2001
• Yamada S. Diane, Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus 2000
• International journal of gynecological cancer
  Monk B J, Expanded polytetrafluoroethylene is an effective barrier in preventing pelvic adhesions after radical surgery for ovarian cancer
  8:5, p. 403 - 408 1998
• Gynecologic oncology
  Monk Bradley J., Photodynamic Therapy Using Topically Applied Dihematoporphyrin Ether in the Treatment of Cervical Intraepithelial Neoplasia
  64:1, p. 70 - 75 1997
• JNCI : Journal of the National Cancer Institute
  Burger Robert A., Human Papillomavirus Type 18: Association With Poor Prognosis in Early Stage Cervical Cancer
  88:19, p. 1361 - 1368 1996
• Obstetrics and gynecology (New York. 1953)
  Monk Bradley J., Prognostic significance of human papillomavirus DNA in vulvar carcinoma
  85:5, p. 709 - 715 1995
• European journal of gynaecological oncology
  Monk B J, Radical hysterectomy after pelvic irradiation in patients with high risk cervical cancer or uterine sarcoma: morbidity and outcome
  14:6, p. 506 - 511 1993
• Gynecologic oncology
  Monk B., The Gore surgical membrane (Gore-SM): Effectiveness as a pelvic lid to limit post-radical pelvic surgery adhesions (PRPSA) in a porcine model
  45:1, p. 87 - 88 1992